Just a few months after buying Timber Pharma, LEO Pharma has revealed that the main drug it acquired as part of the deal has failed a phase 3 trial. Timber's lead candidate TMB-001 for rare skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback